Hims has surged more than 50% this week, as investors focus on the impact of Trump’s Secretary of Health peptide-related policies on the company’s GLP-1 weight-loss drug business transformation.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Earlier this week, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. announced that the Food and Drug Administration (FDA) plans to convene a Drug Compounding Advisory Committee meeting to review whether peptides can be included in the "503A Bulk List". This designation allows drugs to be compounded based on individual prescriptions, rather than mass production.For Hims, the more meaningful story is that as the company guides members towards using branded medications rather than the more profitable compounded GLP-1 drugs, expanding compounding of peptides could open new revenue streams. This telemedicine company has been preparing for the peptide business for years.The FDA's review process has just begun, and the Drug Compounding Advisory Committee meeting is scheduled for July 2026.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Trending news
MoreCrypto prices
MoreBitcoin
BTC
$79,639.22
-1.08%
Ethereum
ETH
$2,256.44
-0.66%
Tether USDt
USDT
$0.9996
-0.00%
BNB
BNB
$669.47
+2.16%
XRP
XRP
$1.42
-0.46%
USDC
USDC
$0.9997
-0.01%
Solana
SOL
$91.12
-3.72%
TRON
TRX
$0.3500
+0.64%
Dogecoin
DOGE
$0.1111
+1.98%
Hyperliquid
HYPE
$38.98
-3.48%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now